

The role of Islet-1 in the endocrine pancreas: Lessons from pancreas specific Islet-1 deficient mice

Catherine Lee May

To cite this article: Catherine Lee May (2010) The role of Islet-1 in the endocrine pancreas: Lessons from pancreas specific Islet-1 deficient mice, *Islets*, 2:2, 121-123, DOI: [10.4161/isl.2.2.10908](https://doi.org/10.4161/isl.2.2.10908)

To link to this article: <http://dx.doi.org/10.4161/isl.2.2.10908>



Copyright © 2010 Landes Bioscience



Published online: 01 Mar 2010.



Submit your article to this journal [↗](#)



Article views: 58



View related articles [↗](#)



Citing articles: 8 View citing articles [↗](#)

The role of islet-1 in the endocrine pancreas

Lessons from pancreas specific islet-1 deficient mice

Catherine Lee May

Department of Pathology and Laboratory Medicine; Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine and Institute of Diabetes for Diabetes, Obesity and Metabolism; Philadelphia, PA USA

Recently, we have reported the LIM-homeodomain (HD) transcriptional regulator, Islet-1 (Isl-1,¹) as a key regulator for pancreatic islets after the secondary transition and into early postnatal stages in mice. Previously, the role of Isl-1 had only been examined during early pancreas development *in vivo*² and cell lines.³⁻⁵ These early studies concluded that Isl-1 is required for the differentiation of early endocrine cells,² and hormone gene expression is regulated by Isl-1 in cell culture.³⁻⁵ However, it was not clear from these studies whether the regulation of hormone gene transcription by Isl-1 was a direct transcriptional event. In addition, the function of Isl-1 during the formation of principle hormone producing endocrine cells had not been investigated since *Isl-1* null animals die prior to the formation of these cells. Using pancreas-specific inactivation of *Isl-1* in mice, we have elucidated the role of Isl-1 during maturation, proliferation and survival of the endocrine pancreas after the secondary transition. We have also identified *MafA*, a potent *Insulin* gene regulator, as the first direct target of Isl-1 in β -cells.

During mouse embryogenesis, the pancreas develops from a pre-patterned domain of the foregut endoderm around embryonic day 9.5 (E9.5). The first visible sign of pancreatic development is the formation of the dorsal and ventral pancreatic buds. At this time, a first wave of endocrine cells expressing glucagon and/or insulin appears as clusters, but these cells do not contribute to the endocrine

compartment of the mature pancreas.⁶⁻⁸ At E13.5, during the secondary transition, coincident with the peak of endocrine and exocrine cell genesis, the generation of the principal population of the endocrine cells that populate the mature pancreas occurs. Over recent years, the analysis of mouse loss-of-function and gain-of-function phenotypes has represented a powerful tool to elucidate pancreas development and has demonstrated the importance of certain transcription factors in the differentiation and function of the endocrine pancreas.^{9,10} However, the complete functional repertoire of one of these islet transcription factors, Islet-1 (Isl-1), remained to be explored.

In 1990, Karlsson and colleagues isolated Isl-1 as an *Insulin* enhancer binding protein by screening a rat islet cell (RIN cell) library.¹ They found expression of Isl-1 restricted to all mature pancreatic islet cells (Fig. 1A).^{11,12} However, during development Isl-1 expression is not only limited to hormone-producing cells (Fig. 1B–D) but is also found in the pancreatic mesenchyme. Interestingly, unlike the first wave Isl-1⁺ endocrine cells that are postmitotic,² we found subsets of Isl-1⁺ cells after the secondary transition possessing proliferating capacity (Fig. 1E and F). The function of Isl-1 in the developing pancreas was first examined using *Isl-1* null animals by Ahlgren and co-workers. They observed dorsal pancreatic bud agenesis and complete loss of first wave hormone-expressing cells in *Isl-1* null embryos.² In addition, Isl-1 has been shown to regulate the expression of hormone genes including proglucagon, somatostatin and

Key words: islet-1, pancreas, transcriptional regulation, diabetes

Submitted: 11/17/09

Revised: 11/30/09

Accepted: 12/08/09

Previously published online:
www.landesbioscience.com/journals/islets/article/10908

Correspondence to: Catherine Lee May;
Email: catheril@mail.med.upenn.edu

Addendum to: Du A, Hunter CS, Murray J, Noble D, Cai C-L, Evans SM, et al. Islet-1 is required for the maturation, proliferation and survival of the endocrine pancreas. *Diabetes* 2009; 58:2059–69; PMID: 19502415; DOI: 10.2337/db08-0987.




Figure 1. Immunostaining of Isl-1 in the pancreas of E14.5, Postnatal day 6 and adult animals. (A) Isl-1 expression (brown) and glucagon expression (blue) in adult islet. (B–D) Immunostaining of Isl-1 (red) with glucagon (green; arrowheads in B), insulin (green; arrowheads in C) and somatostatin (green; arrowhead in D) in E14.5 pancreas. (E and F) Immunostaining of Isl-1 (red; E) and BrdU (brown; F) on P6 pancreatic section. Arrowheads denote Isl-1⁺/BrdU⁺ cells.




Figure 2. Real-time PCR analysis of ChIP DNA from mouse islets shows a 14-fold enrichment for *MafA* as compared with the inactive phosphoenolpyruvate carboxykinase *PEPCK* promoter set as onefold.

insulin in vitro.^{4,5,13} However, due to the lack of better tools at that time to examine direct regulation, these conclusions were based on the use of electrophoretic mobility shift assays (EMSA) and reporter assays in cell lines.

To investigate the role of Isl-1 after the secondary transition, our

group derived pancreas-specific *Isl-1* deficient (*Pdx1-Cre;Isl-1^{L/L}*) mice.¹⁴ *Pdx1-Cre;Isl-1^{L/L}* mice showed progressive loss of islet mass perinatally, characterized by reduced cell proliferation and survival. During development, Isl-1 broadly affects endocrine hormone production without affecting endocrine cell specification. This is supported by the lack of hormone expression in most of the Pax6⁺ endocrine cells in the *Pdx1-Cre;Isl-1^{L/L}* mice.¹⁴ Our observation of downregulation of *MafA* expression, a potent *Insulin* gene regulator, further confirmed the involvement of Isl-1 during final stages of beta cell differentiation. Although hormone gene production was impacted in the *Isl-1* deficient pancreas, we could not detect direct binding of *Insulin* gene by Isl-1 in our chromatin immunoprecipitation assays (ChIP).¹⁴ However, through a series of biochemical studies including EMSA, luciferase reporter experiments and ChIP, we identified *MafA* as a direct transcriptional target of Islet-1 in β TC3 cells and mouse islets (Fig. 2).¹⁴ Our study suggests that the downregulation of *Insulin* expression in the remaining β -cells of the *Pdx1-Cre;Isl-1^{L/L}* mice was partly contributed by the loss of *MafA* expression.¹⁴ Our work clearly demonstrates the importance

of Isl-1 in maturation, proliferation and survival of the endocrine pancreas during early phases of life. The next question is whether Isl-1 is also required for maintaining proper beta mass and function in adult animals. To address this, beta-cell specific and inducible ablation of Isl-1 mice will be necessary since *Pdx1-Cre;Isl-1^{L/L}* mice die from severe hyperglycemia before reaching adulthood.

In summary, our work furthered our understanding of the function of Isl-1 beyond early pancreatic development and uncovered the importance of Isl-1 in both proliferating and postmitotic cells after the secondary transition. Interestingly, a human genetic study of a morbidly obese population suggests the association of *Isl-1* with type 2 diabetes.¹⁵ Furthermore, a nonsense mutation of *Isl-1* gene has been found in a type 2 diabetes Japanese family.¹⁶ These reports along with our work conducted in mice strongly suggest a strong link of Isl-1 to diabetes; however, the precise role of Isl-1 during normal physiology as well as stressed conditions and its direct connection to diabetes awaits further investigation.

Acknowledgements

I would like to express my gratitude to Dr. Klaus Kaestner for critical reading of this addendum. This work was funded by NIH grants DK078606, DK019525 and JDRF 2-2007-703 to C.L.M. Data in this addendum were contributed by Aiping Du and Jingxuan Liu. We also thank the members of the Morphology Core in the Center for Molecular Studies in Digestive and Liver Disease and Penn Diabetes Center for processing the tissue samples (P30-DK050306 and P30-DK19525).

References

1. Karlsson O, Thor S, Norberg T, Ohlsson H, Edlund T. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. *Nature* 1990; 344:879–82.
2. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature* 1997; 385:257–60.
3. Leonard J, Peers B, Johnson T, Ferreri K, Lee S, Montminy MR. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. *Mol Endocrinol* 1993; 7:1275–83.

4. Wang M, Drucker DJ. The LIM domain homeobox gene *isl-1* is a positive regulator of islet cell-specific proglucagon gene transcription. *J Biol Chem* 1995; 270:12646-52.
5. Zhang H, Wang WP, Guo T, Yang JC, Chen P, Ma KT, et al. The LIM-homeodomain protein ISL1 activates insulin gene promoter directly through synergy with BETA2. *J Mol Biol* 2009; 392:566-77.
6. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* 2000; 127:2317-22.
7. Pictet RL, Clark WR, Williams RH, Rutter WJ. An ultrastructural analysis of the developing embryonic pancreas. *Dev Biol* 1972; 29:436-67.
8. Slack JM. Developmental biology of the pancreas. *Development* 1995; 121:1569-80.
9. Collombat P, Hecksher-Sorensen J, Serup P, Mansouri A. Specifying pancreatic endocrine cell fates. *Mechanisms of Development* 2006; 123:501-12.
10. Murtaugh LC. Pancreas and beta-cell development: from the actual to the possible. *Development* 2007; 134:427-38.
11. Dong J, Asa SL, Drucker DJ. Islet cell and extrapancreatic expression of the LIM domain homeobox gene *isl-1*. *Mol Endocrinol* 1991; 5:1633-41.
12. Thor S, Ericson J, Brannstrom T, Edlund T. The homeodomain LIM protein *Isl-1* is expressed in subsets of neurons and endocrine cells in the adult rat. *Neuron* 1991; 7:881-9.
13. Leonard J, Serup P, Gonzalez G, Edlund T, Montminy M. The LIM family transcription factor *Isl-1* requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. *Proc Natl Acad Sci USA* 1992; 89:6247-51.
14. Du A, Hunter CS, Murray J, Noble D, Cai CL, Evans SM, et al. *Isl-1* is required for the maturation, proliferation and survival of the endocrine pancreas. *Diabetes* 2009; 58:2059-69.
15. Barat-Houari M, Clement K, Vatin V, Dina C, Bonhomme G, Vasseur F, et al. Positional candidate gene analysis of Lim domain homeobox gene (*Isl-1*) on chromosome 5q11-q13 in a French morbidly obese population suggests indication for association with type 2 diabetes. *Diabetes* 2002; 51:1640-3.
16. Shimomura H, Sanke T, Hanabusa T, Tsunoda K, Furuta H, Nanjo K. Nonsense mutation of *islet-1* gene (Q310X) found in a type 2 diabetic patient with a strong family history. *Diabetes* 2000; 49:1597-600.

©2010 Landes Bioscience.
Do not distribute.